Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -95.26% is 69% above its 5-year average of -308.10%, near the high end of its 5-year range (-776.06%–39.47%).
61.70% above its 12-month average of -248.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -290.94%.
EBITDA MARGIN
-95.26%
EBITDA MARGIN AVG TTM
-248.74%
EBITDA MARGIN AVG 3Y
-274.65%
EBITDA MARGIN AVG 5Y
-308.10%
EBITDA MARGIN AVG 10Y
-213.60%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+61.70%
CURRENT VS 3Y AVG
+65.32%
CURRENT VS 5Y AVG
+69.08%
CURRENT VS 10Y AVG
+55.40%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Sutro Biopharma, Inc.
Market Cap
$141.49M
EBITDA Margin
-95.26%
TTM Avg
-248.74%
3Y Avg
-274.65%
5Y Avg
-308.10%
Market Cap
$140.67M
EBITDA Margin
-16238.30%
TTM Avg
-8929.91%
3Y Avg
-4730.54%
5Y Avg
-4730.54%
Market Cap
$143.17M
EBITDA Margin
-256.11%
TTM Avg
-256.11%
3Y Avg
-256.11%
5Y Avg
-256.11%
Market Cap
$139.08M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
Market Cap
$143.10M
EBITDA Margin
-783.01%
TTM Avg
-1033.45%
3Y Avg
-1010.27%
5Y Avg
-3715.70%
Market Cap
$143.75M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$137.61M
EBITDA Margin
-5.26%
TTM Avg
-11.06%
3Y Avg
-22.91%
5Y Avg
-20.50%
Market Cap
$138.04M
EBITDA Margin
-410.84%
TTM Avg
-410.84%
3Y Avg
-410.84%
5Y Avg
-410.84%
Market Cap
$145.18M
EBITDA Margin
-239.78%
TTM Avg
-210.59%
3Y Avg
-2213.91%
5Y Avg
-2345.87%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $141.49M | -95.26% | -248.74% | -274.65% | -308.10% |
| Immuneering Corporation (IMRX)vs › | $140.67M | -16238.30% | -8929.91% | -4730.54% | -4730.54% |
| Protara Therapeutics, Inc. (TARA)vs › | $143.17M | -256.11% | -256.11% | -256.11% | -256.11% |
| Alpha Cognition Inc (ACOG)vs › | $139.08M | -221.15% | -221.15% | -221.15% | -221.15% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -783.01% | -1033.45% | -1010.27% | -3715.70% |
| Fortress Biotech, Inc. (FBIOP)vs › | $143.75M | -103.63% | -143.63% | -176.25% | -194.05% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.61M | -5.26% | -11.06% | -22.91% | -20.50% |
| Atrium Therapeutics, Inc. (RNA)vs › | $138.04M | -410.84% | -410.84% | -410.84% | -410.84% |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.18M | -239.78% | -210.59% | -2213.91% | -2345.87% |
| Freenome, Inc. (FRNM)vs › | $135.82M | N/A | N/A | N/A | N/A |
Gross Margin
97.2%
EBITDA Margin
-95.3%
Operating Margin
-102.4%
Net Margin
-395.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -290.94% |
| 2026-03-31 | -195.11% |
| 2025-12-31 | -275.03% |
| 2025-09-30 | -480.34% |
| 2025-06-30 | -2.27% |
| 2025-03-31 | -382.86% |
| 2024-12-31 | -428.05% |
| 2024-09-30 | -776.06% |
| 2024-06-30 | -182.43% |
| 2024-03-31 | -421.51% |
| 2023-12-31 | 39.47% |
| 2023-09-30 | -249.79% |
| 2023-06-30 | -426.89% |
| 2023-03-31 | -320.51% |
| 2022-12-31 | -552.53% |
| 2022-09-30 | -78.63% |
| 2022-06-30 | -64.00% |
| 2022-03-31 | -641.09% |
| 2021-12-31 | -316.51% |
| 2021-09-30 | -393.99% |
| 2021-06-30 | -30.96% |
| 2021-03-31 | -120.86% |
| 2020-12-31 | -285.95% |
| 2020-09-30 | -54.14% |
| 2020-06-30 | -162.19% |
| 2020-03-31 | -252.81% |
| 2019-12-31 | -119.99% |
| 2019-09-30 | -93.70% |
| 2019-06-30 | -118.70% |
| 2019-03-31 | -152.15% |
| 2018-12-31 | -11.21% |
| 2018-09-30 | -115.34% |
| 2018-06-30 | -192.23% |
| 2018-03-31 | -181.96% |
| 2017-12-31 | -345.89% |
| 2017-09-30 | 0.75% |
| 2017-06-30 | -1.45% |
| 2017-03-31 | -1.45% |
